American Home Products Corporation (AHP) is one of the world's largest research-based pharmaceutical and health care products companies and is a leading developer, manufacturer and marketer of prescription drugs and over-the-counter (OTC) medications. It also is a leader in vaccines, biotechnology, agricultural products, animal health care and medical devices.
At a glance, the American Home Products Corporation of 1997 is:
 |
a premier, global health care and crop protection products company with
sales of $14.1 billion, operating in 145 countries; |
 |
a world leader in research and development investment, spending $1.4 billion in overall R&D in 1996; |
 |
the sixth-largest pharmaceutical company in the world in terms of sales; |
 |
among the leaders in sales of non-prescription medications
worldwide and the leader in vitamin sales in the United States; |
 |
a leader in generic pharmaceuticals; |
 |
one of the largest agricultural products companies in the world; |
 |
a leading global medical devices company; and |
 |
a leader in the global animal health care market. |
Throughout its 70-year history, AHP has been evolving from a home products company with a domestic focus to a research-based global pharmaceutical company with premium prescription products, leading OTC brands, innovative medical devices and a dynamic crop protection business. The acquisition of American Cyanamid in 1994 significantly strengthened the Company on a global basis, placing AHP among the top-tier in sales of pharmaceuticals, consumer OTC products, medical devices and animal health care products. AHP also is among the world leaders in sales of crop protection products.
Our Commitment to Research and Development
American Home Products has long been known for its financial acumen and marketing prowess. In 1996, the Company achieved record sales and earnings, and our dividend was increased for the 45th consecutive year.
Today, a substantial capability in R&D can be added to the list of corporate strengths. In 1996, AHP continued its focus on the future with significant investment in R&D. AHP's R&D strategy is to continue to invest in innovative products, which are essential to the long-term success of health care companies. AHP's investment in R&D in 1996 was $1.4 billion, of which $1.1 billion was targeted for pharmaceutical research. This level of spending, six times that of a decade ago, places AHP among the world's leading pharmaceutical companies in terms of R&D commitment.
AHP's pharmaceutical R&D combines the research efforts of Wyeth-Ayerst Research, Genetics Institute and biotech partner Immunex. In addition, research at Cyanamid is generating unique products that are enhancing global agriculture.
The following links may help you quickly find the information you are
looking for:
|